Background: Urtica dioica is extract from the root of a stinging nettle.
Introduction
Benign prostatic hyperplasia (BPH) is the most common disease in aging men (Porst et al., 2013) . BPH leads to lower urinary tract symptoms (LUTS) with storage, voiding, and post-micturition symptoms that adversely affect the individual's health-related quality of life by interfering with normal daily activities and sleep patterns (Hollingsworth et al., 2014) . During recent years, the number of surgical interventions in BPH has decreased in favor of medical treatments (Russo et al., 2014) . The drugs mainly administered for LUTS include α1-blockers, 5α-reductase inhibitors, and phyto-pharmaceuticals. As some α1-blockers may be associated with postural hypotension, and 5α-reductase inhibitors may cause sexual dysfunction (Russo et al., 2014) , there is a great interest in well-tolerated and efficacious herbal remedies. Indeed, drugs from the latter group are still very common all over the world (Chughtai et al., 2013) . the roots of the stinging nettle contain a complex mixture of water-and alcohol-soluble compounds such as fatty acids, sterols (β-sitosterol, campesterol, and stigmasterol), and flavonoids. Urtica dioica has beneficial effects on the treatment of BPH clinical symptoms, and no significant adverse effects have been reported by patients after taking the herb (Lopatkin et There is a general perception that herbal products are, at worst, harmless placebos, but this is not always true. As early as the 15th century BC, the use of plant extracts for the symptomatic treatment of BPH was described on Egyptian papyrus. Unfortunately, many questions remain unanswered; therefore the scientific case for their use remains unproven. The goal of the present study was to perform a meta-analysis to evaluate the safety and efficacy of Urtica dioica in treating BPH, which may resolve some of the current controversies over the use of the drug.
Materials and Methods

Search Strategy
Medline (1966 to Feb 2015), Embase (1974 to Feb 2015 , and Cochrane Controlled Trials Register databases were searched to identify randomized controlled trials (RCTs) that referred to the impact of Urtica dioica in treating BPH; we also searched the reference lists of the retrieved studies. The following search terms were used: Urtica dioica, lower urinary tract symptoms OR lower urinary tract symptom, benign prostatic hyperplasia, randomized controlled trial OR randomized controlled trials .
Inclusion Criteria and Trial Selection
Randomized controlled trials that met the following criteria were included: (1) The study design included treatment with Urtica dioica; (2) the study provided accurate data that could be analyzed, including the total number of subjects and the values of each index; and (3) the full text of the study could be accessed. When the same study was published in various journals or in different years, the most recent publication was used for the meta-analysis. If the same group of researchers studied a group of subjects with multiple experiments, then each study was included. A flow diagram of the study selection process is presented in Figure 1 .
Quality Assessment
The quality of the retrieved RCTs was assessed using the Jadad scale (Jadad, 1998) . All the identified RCTs were included in the meta-analysis regardless of the quality score. The methodological quality of each study was assessed according to how patients were allocated to the arms of the study, the concealment of allocation procedures, blinding, and data loss due to attrition. The studies were then classified qualitatively according to the guidelines published in the Cochrane Handbook for Systematic Reviews of Interventions v.5.1.0 (Higgins et al., 2011) . Based on the quality assessment criteria, each study was rated and assigned to one of the three following quality categories: A, if all quality criteria were adequately met, the study was deemed to have a low risk of bias; B, if one or more of the quality criteria was only partially met or was unclear, the study was deemed to have a moderate risk of bias; or C, if one or more of the criteria was not met or not included, the study was deemed to have a high risk of bias. Differences were resolved by discussion among the authors.
Data Extraction
The following information was collected for each study: (1) the name of the RCT; (2) the study design and sample size; (3) the therapy that the patients received; (4) the country in which the study was conducted; and (5) data including the international prostate symptom score (IPSS), the peak urinary flow rate (Qmax), prostate volume and prostatic specific antigen (PSA).
Statistical Analysis and Meta-Analysis
The meta-analysis of comparable data was carried out using RevMan v.5.1.0 (Cochrane Collaboration, Oxford, UK) (Higgins et al., 2011) . Changes in the IPSS, Qmax, prostate volume and PSA were determined as differences between baseline (study entry) and study completion. We estimated the relative risk for dichotomous outcomes and the standardized mean difference (SMD) for continuous outcomes pooled across studies by using the DerSimonian and Laird random-effects model (DerSimonian et al., 1986 ).
We used a 95% confidence interval (CI). If the result of analysis showed p > 0.05, we considered the studies homogeneous and so chose a fixed-effect model for meta-analysis. Otherwise, a random-effect model was used. We quantified inconsistency using the I² statistic, which describes the proportion of heterogeneity across studies that is not due to chance, thus describing the extent of true inconsistency in results across trials (Higgins et al., 2003) . I² <25% reflects a small level of inconsistency and I² >50% reflects significant inconsistency.
Results
Characteristics of the Individual Studies
The database search found 76 articles that could have been included in our meta-analysis. Based on the inclusion and exclusion criteria, 65 articles were excluded after reading the titles and abstracts of the articles. Six articles lacked useful data. In all, 5 articles (Fig. 1) . The baseline characteristics of the studies included in our meta-analysis are listed in Table 1 .
Quality of the Individual Studies
All 5 RCTs were double blinded, and three of them described the randomization processes that they had used. Four of them included a power calculation to determine the optimal sample size ( Table 2 ). The level of quality of each identified study was
Efficacy
The IPSS
Five RCTs, representing 1,128 participants (573 in the Urtica dioica group and 555 in the control group) (Fig. 3) were
